Literature DB >> 17357211

Palliative treatment of advanced esophageal cancer with metal-covered expandable stents. A cost-effectiveness and quality of life study.

D Xinopoulos1, D Dimitroulopoulos, K Tsamakidis, D Korkolis, A Fotopoulou, A Bazinis, M Kontis, P Vasilopoulos, E Paraskevas.   

Abstract

PURPOSE: The aim of this retrospective study was to evaluate the efficacy and safety of endoscopic therapy with self-expanding metallic endoprostheses in the management of inoperable primary malignant esophageal obstruction or stenosis and the cost-effectiveness of the method. PATIENTS AND METHODS: Between 5/1997-12/2002, obstruction of the esophagus was diagnosed in 78 patients (52 males, 26 females, age range 53-102, mean 72.3 years). The etiology was squamous cell carcinoma (n=42) and adenocarcinoma of the oesophagus (n=36). In total, 89 ultraflex metal stents were introduced endoscopically. In 46 patients dilation with Savary dilators prior to stent placement was required. A cost-effective analysis was performed, comparing oesophageal stenting with laser therapy.
RESULTS: Stents were placed successfully in all patients. After 48 h, all patients were able to tolerate solid or semi-solid food. During the follow-up period 8 patients developed dysphagia due to food impaction (treated successfully endoscopically). Eleven patients developed recurrent dysphagia 4-16 weeks after stenting due to tumor overgrowth and were treated with placement of a second stent. The median survival time was 18 weeks. There was no survival difference between squamous cell and adenocarcinoma of the esophagus. A similar cost was calculated for both procedures. A significant improvement in quality of life was noted in patients undergoing stenting (96% and 75% vs. 71% and 57% for the first two months).
CONCLUSION: Placement of self-expanding metal stents is a safe and cost-effective treatment modality that improves the quality of life, compared with laser therapy, for patients with inoperable malignant esophageal obstruction.

Entities:  

Year:  2005        PMID: 17357211

Source DB:  PubMed          Journal:  J BUON        ISSN: 1107-0625            Impact factor:   2.533


  2 in total

1.  Cost-effectiveness of palliation of unresectable esophageal cancer.

Authors:  Eduardo B da Silveira; Everson L Artifon
Journal:  Dig Dis Sci       Date:  2008-06-04       Impact factor: 3.199

2.  Radiofrequency ablation combined with esophageal stent in the treatment of malignant esophageal stenosis: A single-center prospective study.

Authors:  Yonggui Zhang; Mingwei Zhou; Lin Bai; Rongyan Han; Kang Lv; Zhe Wang
Journal:  Oncol Lett       Date:  2018-06-28       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.